Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$2.14 -2.5%	$2.49	$1.28 ▼ $7.85	$234.24M	1.3	1.55 million shs	558,417 shs
FDMT 4D Molecular Therapeutics	$6.86 +4.3%	$4.77	$2.23 ▼ $17.41	$320.14M	2.83	884,727 shs	593,401 shs
GLUE Monte Rosa Therapeutics	$4.43 +0.8%	$4.95	$3.50 ▼ $12.40	$273.84M	1.42	602,208 shs	337,212 shs
KERN Akerna		$5.89	$0.17 ▼ $6.40	$64.92M	3.02	339,022 shs	70,795 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-6.81%	-10.25%	-5.60%	+11.17%	-63.38%
FDMT 4D Molecular Therapeutics	-9.63%	+6.83%	+55.69%	+85.07%	-55.34%
GLUE Monte Rosa Therapeutics	-3.51%	-1.12%	-25.93%	+9.73%	-9.09%
KERN Akerna	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	2.809 of 5 stars	3.5	3.0	0.0	0.0	3.0	2.5	0.0
FDMT 4D Molecular Therapeutics	2.0842 of 5 stars	3.3	2.0	0.0	0.0	1.6	1.7	0.6
GLUE Monte Rosa Therapeutics	2.0649 of 5 stars	3.3	1.0	0.0	0.0	0.0	1.7	1.9
KERN Akerna	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.75	Moderate Buy	$12.50	485.48% Upside
FDMT 4D Molecular Therapeutics	2.64	Moderate Buy	$30.40	343.47% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	245.81% Upside
KERN Akerna	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KERN, GLUE, ANNX, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANNX Annexon	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/14/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
8/12/2025	FDMT 4D Molecular Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
8/12/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.81 per share	N/A
FDMT 4D Molecular Therapeutics	$33K	9,701.28	N/A	N/A	$9.01 per share	0.76
GLUE Monte Rosa Therapeutics	$177.99M	1.54	N/A	N/A	$4.34 per share	1.02
KERN Akerna	$13.65M	0.00	N/A	N/A	($1.52) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$138.20M	-$1.29	N/A	N/A	N/A	N/A	-70.04%	-57.67%	N/A
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.53	N/A	N/A	N/A	-594,375.81%	-40.15%	-36.43%	N/A
GLUE Monte Rosa Therapeutics	-$72.70M	$0.36	12.32	N/A	N/A	13.58%	9.95%	6.42%	11/6/2025 (Estimated)
KERN Akerna	-$79.06M	-$7.10	N/A	N/A	N/A	-339.99%	N/A	-113.03%	N/A

Latest KERN, GLUE, ANNX, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ANNX Annexon	-$0.36	-$0.34	+$0.02	-$0.34	N/A	N/A
8/11/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.88	-$0.98	-$0.10	-$0.98	$0.52 million	$0.01 million
8/7/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	-$0.15	+$0.16	-$0.15	$7.23 million	$23.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
KERN Akerna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.67	7.99
FDMT 4D Molecular Therapeutics	N/A	8.75	8.75
GLUE Monte Rosa Therapeutics	N/A	7.16	7.16
KERN Akerna	N/A	0.10	0.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
FDMT 4D Molecular Therapeutics	99.27%
GLUE Monte Rosa Therapeutics	79.96%
KERN Akerna	21.97%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	12.67%
FDMT 4D Molecular Therapeutics	9.60%
GLUE Monte Rosa Therapeutics	6.90%
KERN Akerna	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.71 million	95.81 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.70 million	42.22 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.76 million	57.75 million	Optionable
KERN Akerna	112	10.35 million	10.23 million	No Data

KERN, GLUE, ANNX, and FDMT Headlines

Recent News About These Companies

Banzai appoints Dean Ditto as CFO

July 9, 2025 | msn.com

MJ Freeway hit with $4.2M verdict in Pennsylvania contract dispute

December 17, 2024 | greenmarketreport.comG

Pa. Jury Returns $4.2M Verdict in Medical Marijuana Program Dispute

December 13, 2024 | law.comL

Former CNPC chairman arrested on suspicion of accepting bribes, state media says

August 29, 2024 | reuters.com

H.C. Wainwright Sticks to Their Hold Rating for Gryphon Digital Mining (GRYP)

August 24, 2024 | markets.businessinsider.com

Ryan Breslow’s Lead Investor Blindsided By $450 Million Bolt Fundraise: ‘We Were Never In This Deal’

August 22, 2024 | forbes.com

GRYP Gryphon Digital Mining, Inc.

July 19, 2024 | seekingalpha.com

Big Business Runs Illinois Cannabis

April 14, 2024 | southsideweekly.comS

Akerna: Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits

February 13, 2024 | cbonds.comC

Akerna Corp. Simplifies Stock Structure, Alters Fiscal Year

February 10, 2024 | markets.businessinsider.com

Akerna Corp. Announces Completion of Strategic Merger

February 10, 2024 | msn.com

Leading Bitcoin Miner Gryphon Digital Mining Debuts on Nasdaq

February 9, 2024 | finance.yahoo.com

Gryphon Digital Mining, Inc. Debuts on Nasdaq

February 9, 2024 | finanznachrichten.de

Gryphon Digital Mining Debuts on Nasdaq

February 9, 2024 | globenewswire.com

GrowerIQ buys marijuana tech firm Ample Organics from Akerna

January 19, 2024 | mjbizdaily.comM

GrowerIQ acquires cannabis tech competitor Ample Organics from US-based Akerna

January 15, 2024 | betakit.comB

Akerna Announces Special Meeting Date to Vote on Merger with Gryphon Digital Mining, Inc.; Effectiveness of Registration Statement on Form S-4 in Connection with Merger

January 10, 2024 | finance.yahoo.com

Akerna Corp Ordinary Shares

December 19, 2023 | morningstar.comM

10 Effective Ways to Build Buzz Around Your Business

December 12, 2023 | rollingstone.comR

‘Green Wednesday’: Cannabis sales spike day before Thanksgiving

November 23, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KERN, GLUE, ANNX, and FDMT Company Descriptions

Annexon NASDAQ:ANNX

$2.13 -0.06 (-2.51%)

Closing price 03:59 PM Eastern

Extended Trading

$2.14 +0.01 (+0.23%)

As of 04:10 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

4D Molecular Therapeutics NASDAQ:FDMT

$6.86 +0.29 (+4.34%)

Closing price 03:59 PM Eastern

Extended Trading

$6.85 -0.01 (-0.07%)

As of 04:16 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.43 +0.03 (+0.77%)

Closing price 03:59 PM Eastern

Extended Trading

$4.44 +0.01 (+0.14%)

As of 04:10 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Akerna NASDAQ:KERN

Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time